Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study

CONCLUSION: Our results support the clinical utility of the RS assay in ER+ HER2-negative BC with 1 to 3 positive nodes.PMID:34690081 | DOI:10.1016/j.clbc.2021.09.004

Source: Clinical Genitourinary Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Nathalie LeVasseur Julia Sun David Fenton Simon Baxter Angela Chan Sarah Roberts Xiaolan Feng Caroline Lohrisch Karen Gelmon Tamara Shenkier Stephen K Chia Source Type: research